Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include Viral Infections and Outbreaks Research, Viral Infections and Vectors, SARS-CoV-2 and COVID-19 Research, and Viral gastroenteritis research and epidemiology.
IQGAP1 and IQGAP3 are critical host factors for Marburg virus replication, nucleocapsid transport, and cell-to-cell spread.
Lethal Sudan virus infection in IFNAR
<sup>-/-</sup>
mice reveals hallmarks of a cytokine storm
Phase 1 Study of Safety, Reactogenicity, and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate Administered as Inhalation Boost in SARS-CoV-2 Immunized Adults
Discovery of an Antiviral PROTAC Targeting the SARS-CoV-2 Main Protease Using an Allosteric Warhead
Inhaled booster vaccination with an MVA-based SARS-CoV-2 vaccine candidate induces T cell responses in lung
Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans.
Development of a Crystallographic Screening to Identify Sudan Virus VP40 Ligands.
Identification of a Spike-Specific CD8+ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in Humans.
Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection
Inhibition of Rab1B Impairs Trafficking and Maturation of SARS-CoV-2 Spike Protein.
Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice.
SARS-CoV-2 and Epstein-Barr Virus-like Particles Associate and Fuse with Extracellular Vesicles in Virus Neutralization Tests.
The C-terminus of Sudan ebolavirus VP40 contains a functionally important CXnC motif, a target for redox modifications
An introduction to the Marburg virus vaccine consortium, MARVAC
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection
Assembly and transport of filovirus nucleocapsids.
Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein.
Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test.
No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults.
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.
Non‐canonical proline‐tyrosine interactions with multiple host proteins regulate Ebola virus infection
Professor Dr. Hans-Dieter Klenk (1938-2021).
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients
Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study
Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report.
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults